Jea Young Min1,2, Amber J Hackstadt1,3, Marie R Griffin1,2,4, Robert A Greevy1,3, Jonathan Chipman1,3, Carlos G Grijalva1,2, Adriana M Hung1,4, Christianne L Roumie1,4. 1. GRECC, Veterans Health Administration (VHA) Tennessee Valley Healthcare System, Geriatric Research and Education Clinical Center (GRECC), HSR&D Center, Nashville, Tennessee. 2. Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee. 3. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
AIM: To evaluate whether weight change or hypoglycaemia mediates the association between insulin use and death. MATERIALS AND METHODS: In a retrospective cohort of veterans who filled a new prescription for metformin and added insulin or sulphonylurea (2001-2012), we assessed change in body mass index (BMI) and hypoglycaemia during the first 12 months of treatment intensification. Cox proportional hazards models compared the risk of death between treatment groups. Using the difference method, we estimated the indirect effect and proportion mediated through each mediator. A sensitivity analysis assessed mediators in the first 6 months of intensified therapy. RESULTS: Among 28 892 patients surviving 12 months, deaths per 1000 person-years were 15.4 for insulin users and 12.9 for sulphonylurea users (HR 1.20, 95% CI 0.87, 1.64). Change in BMI and hypoglycaemia mediated 13% (-98, 98) and -1% (-37, 71) of this association, respectively. Among 30 214 patients surviving 6 months, deaths per 1000 person-years were 34.8 for insulin users and 21.3 for sulphonylurea users (HR 1.66, 95% CI 1.28, 2.15). Change in BMI and hypoglycaemia mediated 9% (1, 23) and 0% (-9, 4) of this association, respectively. CONCLUSIONS: We observed an increased risk of death among metformin users intensifying treatment with insulin versus sulphonylurea and surviving 6 months of intensified therapy, but not among those surviving 12 months. This association was mediated in part by weight change. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
AIM: To evaluate whether weight change or hypoglycaemia mediates the association between insulin use and death. MATERIALS AND METHODS: In a retrospective cohort of veterans who filled a new prescription for metformin and added insulin or sulphonylurea (2001-2012), we assessed change in body mass index (BMI) and hypoglycaemia during the first 12 months of treatment intensification. Cox proportional hazards models compared the risk of death between treatment groups. Using the difference method, we estimated the indirect effect and proportion mediated through each mediator. A sensitivity analysis assessed mediators in the first 6 months of intensified therapy. RESULTS: Among 28 892 patients surviving 12 months, deaths per 1000 person-years were 15.4 for insulin users and 12.9 for sulphonylurea users (HR 1.20, 95% CI 0.87, 1.64). Change in BMI and hypoglycaemia mediated 13% (-98, 98) and -1% (-37, 71) of this association, respectively. Among 30 214 patients surviving 6 months, deaths per 1000 person-years were 34.8 for insulin users and 21.3 for sulphonylurea users (HR 1.66, 95% CI 1.28, 2.15). Change in BMI and hypoglycaemia mediated 9% (1, 23) and 0% (-9, 4) of this association, respectively. CONCLUSIONS: We observed an increased risk of death among metformin users intensifying treatment with insulin versus sulphonylurea and surviving 6 months of intensified therapy, but not among those surviving 12 months. This association was mediated in part by weight change. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Entities:
Keywords:
hypoglycaemia; insulin therapy; sulphonylureas; type 2 diabetes; weight control
Authors: C Bamia; J Halkjaer; P Lagiou; D Trichopoulos; A Tjønneland; T L Berentzen; K Overvad; F Clavel-Chapelon; M-C Boutron-Ruault; S Rohrmann; J Linseisen; A Steffen; H Boeing; A M May; P H Peeters; H Bas Bueno-de-Mesquita; S W van den Berg; M Dorronsoro; A Barricarte; L Rodriguez Suarez; C Navarro; C A González; P Boffetta; V Pala; G Hallmans; A Trichopoulou Journal: J Intern Med Date: 2010-01-28 Impact factor: 8.989
Authors: Amy Berrington de Gonzalez; Patricia Hartge; James R Cerhan; Alan J Flint; Lindsay Hannan; Robert J MacInnis; Steven C Moore; Geoffrey S Tobias; Hoda Anton-Culver; Laura Beane Freeman; W Lawrence Beeson; Sandra L Clipp; Dallas R English; Aaron R Folsom; D Michal Freedman; Graham Giles; Niclas Hakansson; Katherine D Henderson; Judith Hoffman-Bolton; Jane A Hoppin; Karen L Koenig; I-Min Lee; Martha S Linet; Yikyung Park; Gaia Pocobelli; Arthur Schatzkin; Howard D Sesso; Elisabete Weiderpass; Bradley J Willcox; Alicja Wolk; Anne Zeleniuch-Jacquotte; Walter C Willett; Michael J Thun Journal: N Engl J Med Date: 2010-12-02 Impact factor: 91.245
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Caroline A Presley; Jonathan Chipman; Jea Young Min; Carlos G Grijalva; Robert A Greevy; Marie R Griffin; Christianne L Roumie Journal: J Gerontol A Biol Sci Med Sci Date: 2019-07-12 Impact factor: 6.053
Authors: Christianne L Roumie; Jea Young Min; Robert A Greevy; Carlos G Grijalva; Adriana M Hung; Xulei Liu; Tom Elasy; Marie R Griffin Journal: CMAJ Date: 2016-01-25 Impact factor: 8.262
Authors: Michael E Miller; Denise E Bonds; Hertzel C Gerstein; Elizabeth R Seaquist; Richard M Bergenstal; Jorge Calles-Escandon; R Dale Childress; Timothy E Craven; Robert M Cuddihy; George Dailey; Mark N Feinglos; Farmarz Ismail-Beigi; Joe F Largay; Patrick J O'Connor; Terri Paul; Peter J Savage; Ulrich K Schubart; Ajay Sood; Saul Genuth Journal: BMJ Date: 2010-01-08